GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Preferred Dividends

SER (Serina Therapeutics) Preferred Dividends : $0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Serina Therapeutics's preferred dividends for the three months ended in Mar. 2025 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.


Serina Therapeutics Preferred Dividends Historical Data

The historical data trend for Serina Therapeutics's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Preferred Dividends Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Preferred Dividends
- - - -

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Preferred Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Serina Therapeutics Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.


Serina Therapeutics  (AMEX:SER) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Serina Therapeutics Business Description

Traded in Other Exchanges
Address
601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
Executives
Stephen K. Brannan director C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Jay Venkatesan director C/O AYER CAPITAL MANAGEMENT, LP, 230 CALIFORNIA ST, SUITE 600, SAN FRANCISCO CA 94111
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Gregory S Curhan officer: Chief Financial Officer 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Srini Tenjarla officer: SVP, CMC & Formulation 601 GENOME WAY SUITE 2001, HUNTSVILLE AL 35806
Simba Gill director 515 GALVESTON DR, REDWOOD CITY CA 94063
Tacey Viegas officer: COO and Secretary 601 GENOME WAY SUITE 2001, HUNTSVILLE AL 35806
Randall Moreadith officer: Chief Scientific Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Remy Gross director 601 GENOME WAY SUITE 2001, HUNTSVILLE AL 35806
J Milton Harris director C/O NEKTAR THERAPEUTIC, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Steven A Ledger director, officer: Interim CEO 24 TAMALPAIS AVE, MILL VALLEY CA 94941
Richard Peter Marshall director 601 GENOME WAY SUITE 2001, HUNTSVILLE AL 35806
Steven Mintz director C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Jean-christophe Renondin director 505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022
Juvenescence Us Corp. director, 10 percent owner 303A COLLEGE ROAD EAST, PRINCETON NJ 08540